Neuraxis (NRXS) Debt Ratio (2022 - 2024)

Neuraxis (NRXS) posted Debt Ratio of 0.01 for Q2 2024, down 94.93% sequentially from 0.29 in Q4 2023, and down 41.53% YoY from 0.03 in Q3 2023.

Neuraxis (NRXS) Debt Ratio (2022 - 2024) Analysis & Trends

Neuraxis has reported Debt Ratio for 3 years, with the latest figure at 0.01 in Q2 2024.

Quarterly Debt Ratio fell 41.53% year-over-year to 0.01 in Q2 2024, while the trailing twelve-month figure through Jun 2024 was 0.01 (down 41.53% YoY) and the FY2023 annual result came in at 0.29, up 112.13% from the prior year.
Debt Ratio eased to 0.01 in Q2 2024 per NRXS's latest filing, from 0.29 in the prior quarter.
Over five years, Debt Ratio peaked at 0.29 in Q4 2023 and troughed at 0.01 in Q2 2024.
A 3-year average of 0.12 and a median of 0.14 in 2022 frame the typical range for Debt Ratio.
The sharpest annual moves came in 2023 and 2024: Debt Ratio soared 112.13% in 2023, then plunged 41.53% in 2024.
Over 3 years, Debt Ratio stood at 0.14 in 2022, then jumped by 112.13% to 0.29 in 2023, then plunged by 94.93% to 0.01 in 2024.
According to Business Quant data, Debt Ratio over the past three periods registered 0.01, 0.29, and 0.16 for Q2 2024, Q4 2023, and Q3 2023 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Debt Ratio (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	0.05
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	-
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	0.05
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	0.12
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	-
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	0.03
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	0.26
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	0.47
10	Neuraxis	74.54 Mn	66.21 Mn	-	-

Download Data